NCT05313035View on ClinicalTrials.gov

Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

July 22, 2022

Study Completion Date

February 28, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

SARS-CoV-2 protein subunit recombinant vaccine

candidate vaccine manufactured by PT. Bio Farma

BIOLOGICAL

placebo

the placebo is NaCl injection manufactured by PT. Bio Farma

Trial Locations (3)

Unknown

Faculty of Medicine, Diponegoro University, Semarang, Semarang

Faculty of Medicine Universitas Hassanudin, Makassar

Faculty of Medicine, Universitas Andalas, Padang, Padang

Sponsors

Lead Sponsor

PT Bio Farma
All Listed Sponsors
collaborator

Faculty of Medicine, Universitas Indonesia, Jakarta

UNKNOWN

collaborator

Faculty of Medicine, Diponegoro University, Semarang

UNKNOWN

collaborator

Faculty of Medicine, Universitas Andalas, Padang

UNKNOWN

collaborator

Faculty of Medicine, Universitas Hassanudin, Makassar

UNKNOWN

lead

PT Bio Farma

INDUSTRY